Medical Disclaimer: This information is intended for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be made by a qualified healthcare professional, taking into account the individual patient's condition, preferences, and available resources. Adherence to current local, national, and international guidelines is essential.

---

Diabetic

Overview

• Definition: Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia is associated with long-term damage, dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels.
• Epidemiology:
  • Globally, DM affects over 537 million adults (20-79 years) in 2021, projected to rise to 643 million by 2030 and 783 million by 2045 (IDF Diabetes Atlas, 10th edition).
  • Type 2 Diabetes Mellitus (T2DM) accounts for 90-95% of all DM cases.
  • Type 1 Diabetes Mellitus (T1DM) accounts for 5-10% and is one of the most common chronic diseases in childhood and adolescence.
  • Gestational Diabetes Mellitus (GDM) complicates approximately 2-10% of pregnancies in the U.S.
  • Prediabetes affects over 96 million adults in the U.S. (2022 CDC data).
  • Higher prevalence in certain ethnic groups (e.g., Hispanic, African American, Native American, Asian American populations).
• Classification:
  1. Type 1 Diabetes Mellitus (T1DM): Characterized by autoimmune destruction of pancreatic beta-cells, leading to absolute insulin deficiency.
  2. Type 2 Diabetes Mellitus (T2DM): Characterized by progressive loss of beta-cell insulin secretion, frequently on the background of insulin resistance.
  3. Gestational Diabetes Mellitus (GDM): Diabetes diagnosed in the second or third trimester of pregnancy that was not clearly overt diabetes prior to gestation.
  4. Other Specific Types of Diabetes:
     • Monogenic Diabetes Syndromes: e.g., Maturity-Onset Diabetes of the Young (MODY), neonatal diabetes.
     • Diseases of the Exocrine Pancreas: e.g., Cystic fibrosis-related diabetes, pancreatitis.
     • Drug- or Chemical-Induced Diabetes: e.g., Glucocorticoids, post-transplant diabetes.
     • Endocrinopathies: e.g., Cushing's syndrome, acromegaly.
     • Latent Autoimmune Diabetes in Adults (LADA): A slowly progressing form of autoimmune diabetes, sometimes misdiagnosed as T2DM.

Pathophysiology

• Mechanism:
  • T1DM: Cell-mediated autoimmune destruction of insulin-producing beta-cells in the pancreatic islets. This leads to an absolute deficiency of insulin. Genetic susceptibility (HLA DR3/DR4) and environmental triggers are implicated.
  • T2DM: A complex interplay of genetic predisposition and environmental factors leading to:
    • Insulin Resistance: Peripheral tissues (muscle, liver, fat) fail to respond adequately to insulin, requiring the pancreas to produce more insulin.
    • Beta-Cell Dysfunction: Over time, the pancreatic beta-cells become exhausted and progressively lose their ability to produce sufficient insulin to overcome insulin resistance, leading to hyperglycemia.
    • Increased Hepatic Glucose Production: The liver produces excessive glucose due to impaired insulin action and dysregulation of glucagon.
    • Other defects: Incretin hormone deficiency/resistance (GLP-1, GIP), increased glucagon secretion, increased renal glucose reabsorption, gut microbiome alterations, inflammation.
  • GDM: Placental hormones (e.g., human placental lactogen, estrogen, progesterone, cortisol) induce insulin resistance during pregnancy, particularly in the late second and third trimeters. If the maternal pancreas cannot produce enough insulin to compensate, GDM develops.
• Risk Factors:
  • T1DM: Family history of T1DM, genetics (certain HLA types), geography (higher incidence further from the equator), viral exposures (e.g., enteroviruses), early infant diet.
  • T2DM:
    • Non-modifiable: Family history of DM, ethnicity (African American, Hispanic, Native American, Asian American, Pacific Islander), increasing age.
    • Modifiable: Overweight/obesity (BMI ≥25 kg/m² or ≥23 kg/m² for Asian Americans), physical inactivity, unhealthy diet, prediabetes, history of GDM, polycystic ovary syndrome (PCOS), hypertension (≥140/90 mmHg or on therapy), dyslipidemia (HDL-C <35 mg/dL and/or triglycerides >250 mg/dL), history of cardiovascular disease, non-alcoholic fatty liver disease (NAFLD).
• Protective Factors:
  • T1DM: Currently, no proven primary prevention strategies. Research is ongoing (e.g., oral insulin, anti-CD3 antibodies).
  • T2DM:
    • Lifestyle modifications: Regular physical activity (at least 150 minutes/week of moderate-intensity activity), healthy eating patterns (e.g., Mediterranean diet, DASH diet), achieving and maintaining a healthy weight (5-7% sustained weight loss can significantly reduce risk).
    • Pharmacologic: For individuals with prediabetes and high risk, metformin can reduce the risk of developing T2DM.

Clinical Presentation

Signs and Symptoms

• Cardinal Features:
  • Polyuria: Frequent urination due to osmotic diuresis (glucose exceeding renal threshold).
  • Polydipsia: Increased thirst, compensating for fluid loss.
  • Polyphagia: Increased hunger (more common in T1DM, due to inadequate glucose utilization).
  • Unexplained weight loss: Particularly in T1DM, due to fluid loss and breakdown of fat/muscle for energy.
• Early Signs:
  • Fatigue, lethargy.
  • Blurred vision (due to osmotic changes in the lens).
  • Recurrent infections (e.g., skin infections, candidiasis, UTIs).
  • Slow-healing sores.
  • Numbness or tingling in the hands/feet (early neuropathy).
• Advanced Signs: Manifestations of chronic complications:
  • Cardiovascular: Angina, claudication, stroke symptoms.
  • Neuropathy: Persistent numbness, tingling, burning pain, muscle weakness, foot ulcers, gastroparesis, erectile dysfunction.
  • Nephropathy: Edema (face, legs), foamy urine.
  • Retinopathy: Vision changes, floaters, blindness.
  • Skin changes: Acanthosis nigricans (T2DM), necrobiosis lipoidica diabeticorum, diabetic dermopathy, fungal infections.
  • Diabetic Ketoacidosis (DKA): (More common in T1DM, but can occur in T2DM) Nausea, vomiting, abdominal pain, Kussmaul breathing (deep, rapid), fruity breath odor, altered mental status.
  • Hyperosmolar Hyperglycemic State (HHS): (More common in T2DM) Severe dehydration, altered mental status, profound hyperglycemia.
• Atypical Presentations:
  • Many individuals with T2DM are asymptomatic for years, diagnosed incidentally during routine screening.
  • DKA as the initial presentation of T2DM in some cases (e.g., in stress, infection, or medication non-adherence).
  • Weight gain (common in T2DM) despite hyperglycemia.
  • Isolated neuropathy or retinopathy as initial presentation.

Physical Examination

• Inspection:
  • General: Obesity (especially central adiposity), wasting (T1DM).
  • Skin: Acanthosis nigricans (dark, velvety patches in skin folds), skin tags, necrobiosis lipoidica diabeticorum (shin lesions), diabetic dermopathy (brown spots on shins), eruptive xanthomas, fungal infections (candidiasis, tinea), poor wound healing, diabetic foot ulcers, signs of peripheral artery disease (hair loss, shiny skin, pallor on elevation).
  • Eyes: Fundoscopic examination for retinopathy (microaneurysms, hemorrhages, exudates, neovascularization). Cataracts.
  • Mouth: Periodontal disease.
• Palpation:
  • Cardiovascular: Peripheral pulses (dorsalis pedis, posterior tibial) for diminished or absent pulses (PAD). Carotid bruits.
  • Neurological: Sensation (light touch, pain, temperature, vibration, proprioception). Deep tendon reflexes (ankle reflexes often diminished early).
  • Abdomen: Hepatomegaly (fatty liver).
• Special Tests:
  • Neurological:
    • 10-g Monofilament Test: To assess pressure sensation and identify risk for foot ulceration. Loss of protective sensation.
    • Vibratory sensation: Using a 128-Hz tuning fork on the bony prominences of the foot.
    • Reflexes: Patellar and Achilles reflexes.
  • Foot Examination: Comprehensive annual foot exam including inspection, palpation of pulses, sensory testing.
  • Blood Pressure Measurement: Orthostatic hypotension.
  • Fundoscopy: Direct or indirect ophthalmoscopy for diabetic retinopathy.

Diagnostic Approach

History Taking

• Key Questions:
  • Symptoms: Presence/duration of polyuria, polydipsia, polyphagia, unexplained weight loss, fatigue, blurred vision, numbness/tingling, recurrent infections.
  • Family History: Diabetes in parents, siblings, children (especially T1DM or early-onset T2DM).
  • Medical History: Past medical conditions (e.g., cardiovascular disease, hypertension, dyslipidemia, PCOS, GDM, pancreatitis, cystic fibrosis), current medications (e.g., corticosteroids, immunosuppressants).
  • Social History: Diet, physical activity, smoking, alcohol use.
  • Risk Factors: Overweight/obesity, sedentary lifestyle.
  • For T1DM: History of autoimmune diseases, rapid symptom onset, DKA episodes.
  • For GDM: History of prior GDM, macrosomia, unexplained stillbirth, family history of DM.
• Red Flags:
  • Rapid onset of polyuria, polydipsia, weight loss, especially in children/young adults (suggests T1DM, DKA risk).
  • Nausea, vomiting, abdominal pain, Kussmaul respirations, fruity breath odor, altered mental status (signs of DKA).
  • Severe dehydration, extreme hyperglycemia (>600 mg/dL), significant altered mental status without significant ketosis (signs of HHS).
  • New-onset vision loss or severe neuropathic pain.
  • Non-healing foot ulcers.

Laboratory Tests

• First-Line (Diagnostic Criteria for Diabetes):
  • Fasting Plasma Glucose (FPG): Plasma glucose ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 hours.
  • 2-hour Plasma Glucose (2hPG) during 75-g Oral Glucose Tolerance Test (OGTT): 2hPG ≥200 mg/dL (11.1 mmol/L).
  • Hemoglobin A1c (HbA1c): HbA1c ≥6.5% (48 mmol/mol). (This test must be performed in a laboratory using a method that is NGSP-certified and standardized to the DCCT assay.)
  • Random Plasma Glucose (RPG): Plasma glucose ≥200 mg/dL (11.1 mmol/L) in patients with classic symptoms of hyperglycemia or hyperglycemic crisis.
  • Prediabetes (Increased Risk for Diabetes) Criteria:
    • FPG 100-125 mg/dL (5.6-6.9 mmol/L) (Impaired Fasting Glucose - IFG)
    • 2hPG 140-199 mg/dL (7.8-11.0 mmol/L) during 75-g OGTT (Impaired Glucose Tolerance - IGT)
    • HbA1c 5.7-6.4% (39-47 mmol/mol)
  • Confirmation: In the absence of unequivocal hyperglycemia with acute metabolic decompensation, diagnosis requires two abnormal test results from the same sample or two separate samples.
• Confirmatory (for classification or specific types):
  • C-peptide: To differentiate T1DM (low/undetectable) from T2DM (normal/elevated, especially in early stages). Fasting and/or stimulated (e.g., glucagon stimulation) C-peptide.
  • Autoantibodies: For T1DM diagnosis or differentiation from T2DM/LADA (presence indicates autoimmune process).
    • Islet cell autoantibodies (ICA)
    • Glutamic acid decarboxylase autoantibodies (GADA or anti-GAD65)
    • Insulin autoantibodies (IAA)
    • Insulinoma-associated-2 autoantibodies (IA-2A)
    • Zinc transporter 8 autoantibodies (ZnT8A)
  • Genetic Testing: For monogenic diabetes (e.g., MODY, neonatal diabetes) if suspected.
• Monitoring:
  • HbA1c: Routinely every 3-6 months, or more frequently if glycemic targets are not met or therapy is adjusted.
  • Self-Monitoring of Blood Glucose (SMBG): Frequency varies based on insulin use, treatment regimen, and glycemic control. Continuous Glucose Monitoring (CGM) is increasingly used.
  • Lipid Panel: Annually or more frequently (fasting total cholesterol, LDL-C, HDL-C, triglycerides). Target: LDL-C <100 mg/dL (or <70 mg/dL for high-risk, <55 mg/dL for very high-risk).
  • Urine Albumin-to-Creatinine Ratio (UACR): Annually for T1DM patients for ≥5 years and all T2DM patients. Detects albuminuria (normal <30 mg/g; microalbuminuria 30-300 mg/g; macroalbuminuria >300 mg/g).
  • Estimated Glomerular Filtration Rate (eGFR): Annually (from serum creatinine).
  • Blood Pressure: At every visit. Target: <130/80 mmHg for most adults with DM.
  • Thyroid-stimulating hormone (TSH): Annually in T1DM, and considered in T2DM, especially if symptomatic or with other autoimmune conditions.
  • Vitamin B12: Annually for patients on metformin, especially if symptoms of neuropathy are present.

Imaging

• Recommended (for complications, not primary diagnosis):
  • Retinal photography/Fundoscopy: Annually or biannually for retinopathy screening after dilation (for T1DM, 5 years after diagnosis; for T2DM, at diagnosis).
  • Doppler Ultrasound of peripheral arteries: If peripheral artery disease is suspected (e.g., claudication, abnormal ankle-brachial index).
  • Chest X-ray/CT: If pulmonary complications or infections are suspected.
• Advanced (when needed):
  • Echocardiogram: If heart failure is suspected.
  • Cardiac Stress Testing (ECG or Imaging): For screening for coronary artery disease in high-risk asymptomatic individuals (e.g., with multiple CV risk factors, duration of diabetes >10 years for T2DM or >15 years for T1DM, or microvascular complications), although routine screening is debated. Used to evaluate symptomatic CAD.
  • Carotid Ultrasound: To assess for carotid artery disease in high-risk individuals.
  • MRI/CT: For specific complications (e.g., osteomyelitis in diabetic foot infection, stroke evaluation).

Management

Acute Management

• Immediate:
  • Diabetic Ketoacidosis (DKA):
    • Fluid resuscitation: Isotonic saline (0.9% NaCl) initially, e.g., 15-20 mL/kg/h for first hour, then adjusted based on hydration status and electrolytes.
    • Insulin infusion: Regular insulin 0.1 U/kg IV bolus, then 0.1 U/kg/h continuous infusion. Reduce rate to 0.05-0.1 U/kg/h when glucose reaches 200 mg/dL and add dextrose to IV fluids.
    • Electrolyte replacement: Potassium replacement crucial, even if serum K+ is normal or high, as total body K+ is depleted. Initiate when K+ <5.2 mEq/L. Bicarbonate for severe acidosis (pH <6.9).
  • Hyperosmolar Hyperglycemic State (HHS):
    • Fluid resuscitation: More aggressive fluid resuscitation than DKA due to severe dehydration. Isotonic saline initially, then hypotonic saline (0.45% NaCl) once hemodynamically stable.
    • Insulin infusion: Similar to DKA, but often lower insulin doses are needed as insulin sensitivity is less impaired than in DKA. Initiate after initial fluid resuscitation (to avoid rapid osmotic fluid shifts).
    • Electrolyte replacement: Potassium, similar to DKA.
  • Severe Hypoglycemia (Glucose <54 mg/dL / 3.0 mmol/L):
    • Conscious patient: Oral glucose (15-20g fast-acting carbohydrate, e.g., glucose tablets, 4 oz juice/soda), recheck in 15 mins, repeat if needed.
    • Unconscious/Unable to swallow: Glucagon 1 mg IM/SC (for adults). Or IV Dextrose (D50W 25-50 mL).
• Stabilization:
  • Continuous monitoring of blood glucose, electrolytes (K+, Na+, Cl-, HCO3-), pH (in DKA), fluid balance.
  • Addressing precipitating factors (e.g., infection, MI, medication non-adherence).
• Emergency:
  • Immediate assessment for airway, breathing, circulation in hyperglycemic crisis.
  • Manage complications like cerebral edema (in DKA, particularly in children), rhabdomyolysis, arrythmias.

Chronic Management

• Pharmacological:
  • Type 1 Diabetes Mellitus (T1DM):
    • Insulin replacement therapy: Essential for survival.
      • Basal-bolus regimen: Long-acting insulin (e.g., glargine, detemir, degludec) once or twice daily for basal needs, and rapid-acting insulin (e.g., aspart, lispro, glulisine) before meals/snacks for bolus needs.
      • Insulin pump therapy (CSII): Continuous subcutaneous insulin infusion via a pump.
      • Total Daily Dose (TDD): Typically 0.4-1.0 U/kg/day, starting around 0.5 U/kg/day. Adjust based on glucose monitoring.
      • Insulin-to-Carbohydrate Ratio (ICR): 1 unit insulin per X grams of carbohydrate (e.g., 1:10-1:15).
      • Insulin Sensitivity Factor (ISF) / Correction Factor: Amount of glucose lowering per 1 unit of insulin (e.g., 1 unit lowers glucose by 30-50 mg/dL).
    • Adjunctive Therapies: Pramlintide (amylin analog) to slow gastric emptying, reduce post-prandial glucagon. SGLT2 inhibitors (e.g., empagliflozin, canagliflozin, dapagliflozin) are approved as adjuncts for T1DM with specific indications (e.g., reducing risk of CV death, HF hospitalization, CKD progression) and careful monitoring for DKA.
  • Type 2 Diabetes Mellitus (T2DM):
    • First-line: Metformin (unless contraindicated, e.g., eGFR <30 mL/min/1.73m²). Start at 500 mg daily or BID, titrate up to 1000 mg BID (max 2000-2550 mg/day). Reduces hepatic glucose production, improves insulin sensitivity.
    • Subsequent choices (based on comorbidities, patient factors):
      • GLP-1 Receptor Agonists (GLP-1 RAs) (e.g., liraglutide, semaglutide, dulaglutide, exenatide): Injectable or oral semaglutide. Promote glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, reduce appetite, promote weight loss. Preferred for patients with established ASCVD, CKD, or HF. Many have proven cardiovascular and/or renal benefits.
      • Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2i) (e.g., empagliflozin, canagliflozin, dapagliflozin, ertugliflozin): Increase urinary glucose excretion. Promote weight loss, mild BP reduction. Preferred for patients with established ASCVD, CKD, or HF. Proven cardiovascular and/or renal benefits.
      • Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (e.g., sitagliptin, saxagliptin, linagliptin, alogliptin): Increase levels of endogenous incretins, enhancing glucose-dependent insulin secretion. Weight neutral, generally well-tolerated.
      • Thiazolidinediones (TZDs) (e.g., pioglitazone, rosiglitazone): Improve insulin sensitivity in peripheral tissues. Durable HbA1c lowering. Can cause weight gain, fluid retention, exacerbate HF.
      • Sulfonylureas (SU) (e.g., glipizide, glimepiride, glyburide): Stimulate insulin secretion independent of glucose levels. Risk of hypoglycemia and weight gain. Generally used if cost is a major barrier and CV benefits are not a primary concern.
      • Meglitinides (e.g., repaglinide, nateglinide): Shorter-acting insulin secretagogues, taken before meals. Lower risk of hypoglycemia than SUs.
      • Alpha-Glucosidase Inhibitors (e.g., acarbose, miglitol): Delay carbohydrate absorption in the gut. Modest HbA1c reduction, common GI side effects.
      • Insulin: Often necessary as T2DM progresses. Basal insulin (e.g., glargine, degludec) is often first added, then mealtime insulin if needed.
  • Gestational Diabetes Mellitus (GDM):
    • Medical Nutrition Therapy (MNT) and physical activity are first-line.
    • Insulin: If glucose targets not met. Insulin does not cross the placenta. NPH and regular insulin are commonly used, or insulin analogues like aspart, lispro, glargine, detemir.
    • Metformin or Glyburide: Oral agents may be considered but have limitations and potential risks; insulin is generally preferred.
• Non-pharmacological:
  • Medical Nutrition Therapy (MNT): Individualized meal planning with a registered dietitian, emphasizing balanced macronutrient distribution, whole foods, limiting refined carbohydrates, saturated/trans fats, and added sugars.
  • Physical Activity: At least 150 minutes/week of moderate-intensity aerobic physical activity (e.g., brisk walking) and 2-3 sessions/week of resistance training. Reduce sedentary time.
  • Weight Management: For overweight/obese individuals with T2DM, a 5% or greater weight loss can significantly improve glycemic control and reduce CV risk. Bariatric surgery may be considered for BMI ≥35 kg/m² with DM.
  • Smoking Cessation: Crucial due to increased risk of cardiovascular disease, microvascular complications, and premature mortality.
  • Diabetes Self-Management Education and Support (DSMES): Comprehensive education on diet, medication, monitoring, foot care, sick day rules, and problem-solving.
  • Psychosocial Support: Address diabetes distress, depression, anxiety, and eating disorders.
• Monitoring:
  • Glycemic Control:
    • HbA1c Target: Generally <7.0% for most non-pregnant adults. Individualized targets based on age, comorbidities, duration of diabetes, risk of hypoglycemia, and patient preferences (e.g., <6.5% for younger patients with few comorbidities, >7.5-8.0% for elderly/frail patients with significant comorbidities/hypoglycemia risk).
    • SMBG: Daily for insulin-treated patients (pre-meal, 2h post-meal, bedtime, overnight if indicated). Less frequent for non-insulin treated.
    • CGM: Increasingly used for T1DM and insulin-treated T2DM to reduce hypoglycemia and improve time in range.
  • Blood Pressure: At every routine visit. Target generally <130/80 mmHg. Lifestyle modifications and pharmacological agents (ACE inhibitors/ARBs often first-line, especially if albuminuria present).
  • Lipid Management: Annually. Statin therapy for most adults with DM, intensity based on ASCVD risk. Target LDL-C: <100 mg/dL for most, <70 mg/dL for those aged 40-75 with ASCVD risk factors, <55 mg/dL for those with established ASCVD.
  • Kidney Disease Screening: Annually with UACR and eGFR. ACE inhibitors/ARBs for albuminuria. SGLT2 inhibitors and GLP-1 RAs have renoprotective benefits.
  • Eye Care: Annual dilated comprehensive eye exam.
  • Foot Care: Annual comprehensive foot exam (monofilament, pulses, inspection). Daily self-foot checks.
  • Dental Care: Regular dental check-ups (every 6 months) for periodontal disease.

Treatment Algorithms (Based on ADA/EASD consensus)

• First-Line:
  • T1DM: Lifelong insulin therapy. Basal-bolus or insulin pump.
  • T2DM: Lifestyle management + Metformin (unless contraindicated).
• Second-Line (for T2DM, if HbA1c target not met after 3 months, or based on comorbidities):
  • Prioritize agents with proven ASCVD benefit, CKD benefit, or HF benefit:
    • If established ASCVD or high ASCVD risk (age ≥55 with 2+ risk factors, subclinical ASCVD): Add GLP-1 RA or SGLT2i (preferred).
    • If Heart Failure (HF) (especially HFrEF): Add SGLT2i (preferred).
    • If Chronic Kidney Disease (CKD) (eGFR <60 mL/min/1.73m² or UACR >30 mg/g): Add SGLT2i (preferred), or GLP-1 RA if SGLT2i not tolerated/indicated.
  • If no established ASCVD/CKD/HF, and compelling need for weight loss: Consider GLP-1 RA or SGLT2i.
  • If no compelling indicators and need to minimize hypoglycemia: Consider DPP-4i, GLP-1 RA, SGLT2i, or TZD.
  • If cost is a major consideration: Consider Sulfonylurea or TZD.
• Third-Line (for T2DM, if targets not met with dual/triple therapy):
  • Intensify current regimen by adding another agent from a different class.
  • Consider insulin (basal insulin initially, then add mealtime insulin as needed).
  • Consider combination injectable therapy (e.g., GLP-1 RA + basal insulin).
• Refractory Cases:
  • Intensified Insulin Regimens: Multiple daily injections (MDI) or insulin pump therapy.
  • Bariatric Surgery: For patients with T2DM and BMI ≥40 kg/m² (or BMI ≥35 kg/m² with severe comorbidities) and sometimes for BMI 30-34.9 kg/m² with inadequately controlled diabetes.
  • Pancreas or Islet Cell Transplantation: For select patients with T1DM, especially those with recurrent severe hypoglycemia or kidney failure undergoing kidney transplant.
  • Referral to Diabetes Specialist: For complex cases, brittle diabetes, or persistent glycemic control issues.

Complications

• Common:
  • Hypoglycemia: Low blood glucose, especially with insulin or sulfonylureas.
  • Diabetic Ketoacidosis (DKA): Acute, life-threatening metabolic emergency (mainly T1DM).
  • Hyperosmolar Hyperglycemic State (HHS): Acute, life-threatening emergency (mainly T2DM).
  • Neuropathy:
    • Peripheral (symmetrical polyneuropathy, mononeuropathy, mononeuropathy multiplex).
    • Autonomic (gastroparesis, erectile dysfunction, orthostatic hypotension, diabetic diarrhea, neurogenic bladder).
  • Retinopathy: Non-proliferative and proliferative forms, macular edema. Leading cause of new blindness in working-age adults.
  • Nephropathy: Microalbuminuria, proteinuria, progressive decline in GFR, end-stage renal disease (ESRD). Leading cause of ESRD.
  • Macrovascular Disease: Atherosclerosis affecting large vessels.
    • Coronary Artery Disease (CAD): Myocardial infarction, angina.
    • Cerebrovascular Disease (CVD): Stroke, transient ischemic attack (TIA).
    • Peripheral Artery Disease (PAD): Claudication, non-healing foot ulcers, amputations.
• Serious:
  • Cardiovascular events: Myocardial infarction, stroke, heart failure.
  • End-stage Renal Disease (ESRD): Requiring dialysis or kidney transplant.
  • Blindness.
  • Non-traumatic amputations (due to neuropathy, PAD, infection).
  • Severe infections: Diabetic foot infections, osteomyelitis, necrotizing fasciitis.
  • Increased susceptibility to common infections: Pneumonia, influenza, UTIs.
  • Diabetic Coma (due to DKA, HHS, or severe hypoglycemia).
• Long-term:
  • Chronic Kidney Disease (CKD).
  • Advanced Cardiovascular Disease.
  • Diabetic Foot Syndrome: Ulcers, Charcot neuroarthropathy, infections, amputations.
  • Periodontal Disease.
  • Sexual Dysfunction: Erectile dysfunction in men, vaginal dryness/dyspareunia in women.
  • Gastroparesis: Nausea, vomiting, early satiety, erratic glucose control.
  • Depression and Anxiety: Higher prevalence in people with diabetes.
  • Cognitive Decline/Dementia: Increased risk.
  • Increased risk of certain cancers: Liver, pancreas, colon, breast, bladder.
  • Non-alcoholic Fatty Liver Disease (NAFLD) / Non-alcoholic Steatohepatitis (NASH).

Prognosis

• Factors:
  • Glycemic Control: Achieving and maintaining individualized HbA1c targets significantly reduces microvascular and macrovascular complications.
  • Blood Pressure Control: Strict BP management significantly reduces cardiovascular events and progression of kidney disease.
  • Lipid Management: Aggressive LDL-C lowering reduces ASCVD events.
  • Duration of Diabetes: Longer duration increases risk of complications.
  • Presence of Complications at Diagnosis: Determines initial prognosis.
  • Comorbidities: Heart disease, kidney disease, obesity.
  • Lifestyle Factors: Diet, physical activity, smoking cessation.
  • Adherence to Treatment and Self-Care: Crucial for long-term outcomes.
• Survival:
  • Diabetes reduces life expectancy by 6-10 years on average.
  • Cardiovascular disease is the leading cause of morbidity and mortality in both T1DM and T2DM.
  • Improved management strategies (intensive glycemic control, BP, lipid control, newer medications with CV/renal benefits) have shown to improve survival and reduce complication rates.
• Quality of Life:
  • Complications can significantly impair quality of life, leading to disability, pain, and reduced functional independence.
  • Diabetes distress, depression, and anxiety are common and further reduce QOL.
  • Comprehensive, patient-centered care focusing on education, self-management, and psychosocial support can significantly improve quality of life and reduce disease burden.

Prevention

• Primary: Preventing the initial occurrence of diabetes.
  • For T2DM:
    • Intensive Lifestyle Interventions: For individuals with prediabetes. Goals: ≥7% weight loss, ≥150 minutes/week of moderate-intensity physical activity.
    • Pharmacologic Prevention: Metformin can be considered for individuals with prediabetes (especially those with BMI ≥35 kg/m², age <60 years, or history of GDM) if lifestyle interventions are insufficient.
  • For T1DM: Currently no established primary prevention strategies outside of research settings.
• Secondary: Early detection and intervention to prevent or delay the onset of complications.
  • Screening:
    • T2DM: Screen asymptomatic adults with overweight/obesity (BMI ≥25 kg/m² or ≥23 kg/m² in Asian Americans) and at least one additional risk factor. If no risk factors, begin screening at age 35 years. Repeat every 3 years if results are normal.
    • GDM: Screen all pregnant women not known to have diabetes at 24-28 weeks of gestation using a 1-step 75-g OGTT or 2-step approach (50-g glucose challenge test followed by 100-g OGTT if abnormal).
  • Intensive Glucose Control: Early and sustained glycemic control after diagnosis significantly reduces the risk of microvascular complications (e.g., retinopathy, nephropathy, neuropathy) and macrovascular events.
  • Blood Pressure and Lipid Management: Early and aggressive management of hypertension and dyslipidemia to reduce cardiovascular risk.
• Tertiary: Preventing progression of complications and maximizing quality of life in individuals with established diabetes.
  • Aggressive management of risk factors: Tight glycemic, BP, and lipid control.
  • Regular Screening for Complications: Annual eye exams, foot exams, kidney disease screening (UACR, eGFR).
  • Early Intervention for Complications: e.g., ACE inhibitors/ARBs for albuminuria, laser photocoagulation or anti-VEGF injections for retinopathy, appropriate foot care to prevent ulcers/amputations.
  • Comprehensive Diabetes Education: To empower patients in self-management.

Special Populations

• Pediatric:
  • T1DM is predominant. Management focuses on insulin therapy (basal-bolus or pump), carb counting, frequent glucose monitoring (often CGM), and balancing growth/development with glycemic control.
  • Psychosocial impact: Significant burden on children and families; depression/anxiety common.
  • DKA risk: Higher in young children, requires rapid recognition.
  • Transition of care: Critical period from pediatric to adult diabetes care.
• Geriatric:
  • Individualized HbA1c targets: Less stringent (e.g., 7.0-8.0%) due to increased risk of hypoglycemia, comorbidities, polypharmacy, and limited life expectancy.
  • Prioritize avoiding hypoglycemia: May be more dangerous and difficult to recognize.
  • Comorbidities: High prevalence of cardiovascular disease, cognitive impairment, functional limitations.
  • Medication choices: Consider renal function, potential drug interactions, and tolerability. Avoid drugs with high hypoglycemia risk if possible.
  • Foot care and falls prevention: Crucial due to neuropathy and vision impairment.
• Pregnancy:
  • Pre-existing Diabetes (Type 1 or 2):
    • Preconception counseling: Optimize glucose control (HbA1c <6.5%) before conception to minimize congenital anomalies and maternal/fetal complications.
    • Intensive management: Tight glycemic control throughout pregnancy (FPG <95 mg/dL, 1-h PPG <140 mg/dL, 2-h PPG <120 mg/dL). Insulin is the preferred pharmacotherapy.
    • Screening for complications: Early retinopathy and nephropathy screening.
  • Gestational Diabetes Mellitus (GDM):
    • Management: Lifestyle modification first-line. If not sufficient, insulin is preferred. Oral agents (metformin, glyburide) may be considered with careful risk-benefit discussion.
    • Postpartum follow-up: All women with GDM should be screened for persistent diabetes at 4-12 weeks postpartum (75-g OGTT). Lifelong screening for T2DM every 1-3 years due to high risk.
• Comorbidities:
  • Cardiovascular Disease (CVD): Prioritize GLP-1 RAs and SGLT2i due to proven CV benefits. Aggressive BP and lipid management. Antiplatelet therapy as indicated for secondary prevention.
  • Chronic Kidney Disease (CKD): Prioritize SGLT2i and GLP-1 RAs. Adjust medication dosages based on eGFR. Avoid metformin if eGFR <30 mL/min/1.73m².
  • Heart Failure (HF): SGLT2i are strongly recommended for patients with T2DM and HF (especially HFrEF). Avoid TZDs.
  • Obesity: GLP-1 RAs and SGLT2i are preferred due to weight loss benefits. Consider bariatric surgery for eligible patients.
  • Mental Health: Screen for depression, anxiety, and diabetes distress. Integrate mental health support into diabetes care.

Clinical Pearls

• Diagnostic:
  • Don't rely solely on HbA1c: While convenient, it doesn't capture glycemic variability or recent acute hyperglycemia. FPG and OGTT may be needed, especially if HbA1c is discordant with clinical picture or in conditions affecting red blood cell turnover (e.g., anemia, hemoglobinopathies).
  • Consider T1DM in adults: LADA can be misdiagnosed as T2DM. Antibody testing and C-peptide can differentiate.
  • Prediabetes is a critical warning: It's an opportunity for intensive lifestyle intervention to prevent overt diabetes.
• Treatment:
  • Individualize glycemic targets: "One size does not fit all." Tailor HbA1c goals based on patient age, comorbidities, duration of diabetes, and risk of hypoglycemia.
  • Prioritize agents with cardiorenal benefits: For most patients with T2DM and established ASCVD, CKD, or HF, GLP-1 RAs or SGLT2i should be included in the regimen, independent of HbA1c.
  • Address therapeutic inertia: Don't delay intensification of therapy if targets are not met. Re-evaluate and adjust medications every 3-6 months.
  • Patient education is paramount: Empower patients through comprehensive DSMES, focusing on self-management skills, medication adherence, and complication prevention.
• Pitfalls:
  • Ignoring hypoglycemia: Underrated risk, especially in elderly or those with hypoglycemia unawareness. Can lead to falls, CV events, cognitive impairment.
  • Neglecting foot care: A common cause of preventable amputations. Emphasize daily foot checks and professional podiatric care.
  • Focusing only on glucose: Holistic diabetes management requires concurrent management of blood pressure, lipids, weight, and smoking cessation.
  • Overlooking psychosocial issues: Diabetes distress, depression, and anxiety significantly impact adherence and outcomes. Screen and refer as appropriate.
  • Missing early complications: Regular screening for retinopathy, nephropathy, and neuropathy is crucial for timely intervention.

Recent Updates

• Guidelines:
  • American Diabetes Association (ADA) Standards of Medical Care in Diabetes (updated annually).
  • European Association for the Study of Diabetes (EASD) and ADA Consensus Report.
  • American Association of Clinical Endocrinology (AACE)/American College of Endocrinology (ACE) Clinical Practice Guidelines.
• Evidence:
  • Strong evidence for cardiovascular and renal benefits of SGLT2 inhibitors and GLP-1 receptor agonists in patients with T2DM, independent of glycemic control. This has fundamentally shifted treatment paradigms to prioritize these agents in patients with established ASCVD, HF, or CKD.
  • Emerging evidence for SGLT2 inhibitors in reducing heart failure hospitalization and slowing CKD progression in patients without diabetes.
  • Increased focus on weight management and obesity treatment as central to T2DM management, given the strong link between obesity and insulin resistance. New highly effective anti-obesity medications are being developed.
  • Continuous Glucose Monitoring (CGM) technology has advanced significantly, becoming more widely used in both T1DM and T2DM, demonstrating improved time in range and reduced hypoglycemia compared to SMBG alone.
• Controversies:
  • Optimal glycemic targets in frail elderly patients: Balancing the benefits of tight control against the risks of hypoglycemia and polypharmacy.
  • Role of bariatric/metabolic surgery in patients with lower BMI (e.g., BMI 30-35 kg/m²) with inadequately controlled T2DM.
  • Management of diabetes in non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH): Specific therapeutic approaches are evolving.

Key References

• Guidelines:
  • American Diabetes Association. Standards of Medical Care in Diabetes—[Current Year]. Diabetes Care. (Published annually in January)
  • Davies MJ, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2022;45:2753-2786.
  • Garber AJ, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm—[Current Year]. Endocrine Practice. (Published annually)
• Studies:
  • DCCT (Diabetes Control and Complications Trial): Seminal trial demonstrating intensive glycemic control reduces microvascular complications in T1DM. N Engl J Med 1993;329:977-86.
  • UKPDS (United Kingdom Prospective Diabetes Study): Showed that intensive glucose control and BP control reduce microvascular and macrovascular complications in T2DM. Lancet 1998;352:837-53.
  • EMPA-REG OUTCOME, LEADER, CANVAS, DECLARE-TIMI 58, VERTIS CV: Landmark cardiovascular outcome trials (CVOTs) for SGLT2 inhibitors and GLP-1 receptor agonists demonstrating cardiovascular and/or renal benefits in T2DM.
  • DAPA-CKD, EMPA-KIDNEY: Trials demonstrating kidney and heart failure benefits of SGLT2 inhibitors in patients with and without diabetes.
• Reviews:
  • UpToDate: Extensive topic reviews on all aspects of diabetes management.
  • Harrison's Principles of Internal Medicine: Comprehensive textbook chapters on diabetes.
  • Braunwald's Heart Disease: Textbook chapters focusing on diabetes and cardiovascular disease.